دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Consumption of Olive Oil and Risk of Total and Cause-Specific Mortality Among U.S. Adults
MartaGuasch-FerréPhDabYanpingLiPhDaWalter C.WillettMD, DrPHabcQiSunMD, ScDabcdLauraSampsonRDaJordiSalas-SalvadóMDefMiguel A.MartÃnez-GonzálezMDaegMeir J.StampferMD, DrPHabcFrank B.HuMD, PhDabc
doi : 10.1016/j.jacc.2021.10.041
Volume 79, Issue 2, 18 January 2022, Pages 101-112
Olive oil consumption has been shown to lower cardiovascular disease risk, but its associations with total and cause-specific mortality are unclear.
Can Small Amounts of Olive Oil Keep the Death Away?∗
Susanna C.LarssonPhD
doi : 10.1016/j.jacc.2021.11.006
Volume 79, Issue 2, 18 January 2022, Pages 113-115
Magnetically Controlled Capsule Endoscopy for Assessment of Antiplatelet Therapy–Induced Gastrointestinal Injury
YalingHanMDa∗ZhuanLiaoMDb∗YiLiMDaXianxianZhaoMDbShurenMaMDaDanBaoMDaMiaohanQiuMDaJieDengMDcJinhaiWangMDcPengQuMDdChunmengJiangMDdShaobinJiaMDeShaoqiYangMDeLeishengRuMDfJiaFengMDfWeiGaoMDgYonghuiHuangMDgLingTaoMDh…Gregg W.StoneMDn
doi : 10.1016/j.jacc.2021.10.028
Volume 79, Issue 2, 18 January 2022, Pages 116-128
Gastrointestinal bleeding is the most frequent major complication of antiplatelet therapy. In patients at low bleeding risk, however, clinically overt gastrointestinal bleeding is relatively uncommon.
Gastrointestinal Injury Caused by Aspirin or Clopidogrel Monotherapy Versus Dual Antiplatelet Therapy∗
John A.BittlMDaLorenLaineMDbc
doi : 10.1016/j.jacc.2021.10.027
Volume 79, Issue 2, 18 January 2022, Pages 129-131
Risk-Adjusted, 30-Day Home Time After Transcatheter Aortic Valve Replacement as a Hospital-Level Performance Metric
AmgadMentiasMD, MSaNeilKeshvaniMDbMilind Y.DesaiMD, MBAaDharam J.KumbhaniMD, SMbMary VaughanSarrazinPhDcdYuboGaoPhDcdSamirKapadiaMDaEric D.PetersonMD, MPHbMichaelMackMDeSaketGirotraMD, SMcfAmbarishPandeyMD, MSCSb
doi : 10.1016/j.jacc.2021.10.038
Volume 79, Issue 2, 18 January 2022, Pages 132-144
Patient-centric measures of hospital performance for transcatheter aortic valve replacement (TAVR) are needed.
For TAVR, Home Is Where the Heart Is∗
Matthew W.SherwoodMD, MHSabAmit N.VoraMD, MPHcd
doi : 10.1016/j.jacc.2021.10.039
Volume 79, Issue 2, 18 January 2022, Pages 145-147
Feasibility and Potential Impact of Heart Transplantation From Adult Donors After Circulatory Death
ShivankMadanMD, MHAaOmarSaeedMDaStephen J.ForestMDbDaniel J.GoldsteinMDbUlrich P.JordeMDaSnehal R.PatelMDa
doi : 10.1016/j.jacc.2021.10.042
Volume 79, Issue 2, 18 January 2022, Pages 148-162
A shortage of donation after brain death (DBD) donors for heart transplantation (HT) persists. Recent improvements in organ procurement from donation after circulatory death (DCD) donors and promising early results of DCD-HTs from Europe and Australia have renewed interest in DCD-HT.
Heart Transplantation Using Organs From Donors Following Circulatory Death: The Journey Continues∗
Francis D.PaganiMD, PhD
doi : 10.1016/j.jacc.2021.11.008
Volume 79, Issue 2, 18 January 2022, Pages 163-165
Management of Atrial Fibrillation in Patients 75 Years and Older: JACC State-of-the-Art Review
Annabelle SantosVolgmanMDaGathaNairMDaRadmilaLyubarovaMDbFaisal M.MerchantMDcPamelaMasondAnne B.CurtisMDeNanette K.WengerMDcNeelum T.AggarwalMDfJames N.KirkpatrickMDgEmelia J.BenjaminMD, ScMh
doi : 10.1016/j.jacc.2021.10.037
Volume 79, Issue 2, 18 January 2022, Pages 166-179
The prevalence of atrial fibrillation (AF) is increasing as the population ages. AF treatment-related complications also increase markedly in older adults (defined as ≥75 years of age for this review). The older AF population has a high risk of stroke, bleeding, and death. Syncope and fall-related injuries are the most common reasons for nonprescription of oral anticoagulation (OAC), and are more common in older adults when OACs are used with antiarrhythmic drugs. Digoxin may be useful for rate control, but associations with increased mortality limit its use. Beyond rate and rhythm control considerations, stroke prophylaxis is critical to AF management, and the benefits of direct OACs, compared with warfarin, extend to older adults. Invasive procedures such as AF catheter ablation, pacemaker implantation/atrioventricular junction ablation, and left atrial appendage occlusion may be useful in appropriately selected cases. However, older adults have generally been under-represented in clinical trials.
Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease: JACC Review Topic of the Week
AlessandroMantovaniMDa∗Christopher D.ByrneMB, BChb∗GiovanniBenfariMDcStefanoBonapaceMDdTracey G.SimonMDefGiovanniTargherMDa
doi : 10.1016/j.jacc.2021.11.007
Volume 79, Issue 2, 18 January 2022, Pages 180-191
Heart failure (HF) and nonalcoholic fatty liver disease (NAFLD) are 2 conditions that have become important global public health problems. Emerging evidence supports a strong and independent association between NAFLD and the risk of new-onset HF, and there are multiple potential pathophysiological mechanisms by which NAFLD may increase risk of new-onset HF. The magnitude of this risk parallels the underlying severity of NAFLD, especially the level of liver fibrosis. Patients with NAFLD develop accelerated coronary atherosclerosis, myocardial alterations (mainly cardiac remodeling and hypertrophy), and certain arrhythmias (mainly atrial fibrillation), which may precede and promote the development of new-onset HF. This brief narrative review aims to provide an overview of the association between NAFLD and increased risk of new-onset HF, discuss the underlying mechanisms that link these 2 diseases, and summarize targeted pharmacological treatments for NAFLD that might also reduce the risk of HF.
The Heart Valve Collaboratory: A Disruptive Model in the Management of Valvular Heart Disease
Michael J.MackMDaMartin B.LeonMDbcChangfuWuPhDdBramZuckermanMDdHeart Valve Collaboratory Scientific Council
doi : 10.1016/j.jacc.2021.10.040
Volume 79, Issue 2, 18 January 2022, Pages 192-196
2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Writing Committee Members∗Jennifer S.LawtonMD, FAHA(Chair)†Jacqueline E.Tamis-HollandMD, FAHA, FACC, FSCAI(Vice Chair)‡SripalBangaloreMD, MHA, FACC, FAHA, FSCAI†Eric R.BatesMD, FACC, FAHA†Theresa M.BeckiePhD, FAHA†James M.BischoffMEd†John A.BittlMD, FACC, FAHA†Mauricio G.CohenMD, FACC, FSCAI§J. MichaelDiMaioMD†Creighton W.DonMD, PhD, FACC‖Stephen E.FremesMD, FACCMario F.GaudinoMD, PhD, MSCE, FACC, FAHA†Zachary D.GoldbergerMD, FACC, FAHA‡Michael C.GrantMD, MSE†Jang B.JaswalMS†Paul A.KurlanskyMD, FACC†RoxanaMehranMD, FACC†…Brittany A.ZwischenbergerMDâ€
doi : 10.1016/j.jacc.2021.09.005
Volume 79, Issue 2, 18 January 2022, Pages 197-215
The executive summary of the American College of Cardiology/American Heart Association/Society for Cardiovascular Angiography and Interventions coronary artery revascularization guideline provides the top 10 items readers should know about the guideline. In the full guideline, the recommendations replace the 2011 coronary artery bypass graft surgery guideline and the 2011 and 2015 percutaneous coronary intervention guidelines. This summary offers a patient-centric approach to guide clinicians in the treatment of patients with significant coronary artery disease undergoing coronary revascularization, as well as the supporting documentation to encourage their use.
2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Writing Committee Members∗Jennifer S.LawtonMD, FAHA(Chair)†Jacqueline E.Tamis-HollandMD, FAHA, FACC, FSCAI(Vice Chair)‡SripalBangaloreMD, MHA, FACC, FAHA, FSCAI†Eric R.BatesMD, FACC, FAHA†Theresa M.BeckiePhD, FAHA†James M.BischoffMEd†John A.BittlMD, FACC†Mauricio G.CohenMD, FACC, FSCAI§J. MichaelDiMaioMD†Creighton W.DonMD, PhD, FACC||Stephen E.FremesMD, FACCMario F.GaudinoMD, PhD, MSCE, FACC, FAHA†Zachary D.GoldbergerMD, FACC, FAHA‡Michael C.GrantMD, MSE†Jang B.JaswalMS†Paul A.KurlanskyMD, FACC†RoxanaMehranMD, FACC†…Brittany A.ZwischenbergerMDâ€
doi : 10.1016/j.jacc.2021.09.006
Volume 79, Issue 2, 18 January 2022, Pages e21-e129
The guideline for coronary artery revascularization replaces the 2011 coronary artery bypass graft surgery and the 2011 and 2015 percutaneous coronary intervention guidelines, providing a patient-centric approach to guide clinicians in the treatment of patients with significant coronary artery disease undergoing coronary revascularization as well as the supporting documentation to encourage their use.
Lessons From the COVID-19 Pandemic: Clinical Guidance and Respect for Science
DiptiItchhaporiaMD, FACC(President, American College of Cardiology)
doi : 10.1016/j.jacc.2021.12.001
Volume 79, Issue 2, 18 January 2022, Pages 216-219
Consistency of Benefit of Icosapent Ethyl by Background Statin Type in REDUCE-IT
NickpreetSinghMD, MSDeepak L.BhattMD, MPHMichaelMillerMDPh. GabrielStegMDEliot A.BrintonMDTerry A.JacobsonMDLixiaJiaoPhDJean-ClaudeTardifMDR. PrestonMasonPhDChristie M.BallantyneMDREDUCE-IT Investigators
doi : 10.1016/j.jacc.2021.11.005
Volume 79, Issue 2, 18 January 2022, Pages 220-222
Cardiovascular Disease Is the Condition, Air Pollution the Risk Factor, Fossil Fuel Combustion the Cause
Alan P.JacobsenMB BCh BAORoger S.BlumenthalMD
doi : 10.1016/j.jacc.2021.09.1386
Volume 79, Issue 2, 18 January 2022, Page e131
Reply: Cardiovascular Disease Is the Condition, Air Pollution the Risk Factor, Fossil Fuel Combustion the Cause
TiantianLiPhDYiZhangMPHMike Z.HePhDXiaomingShiMD
doi : 10.1016/j.jacc.2021.10.036
Volume 79, Issue 2, 18 January 2022, Page e133
Consumption of Olive Oil and Risk of Total and Cause-Specific Mortality Among U.S. Adults
MartaGuasch-FerréPhDabYanpingLiPhDaWalter C.WillettMD, DrPHabcQiSunMD, ScDabcdLauraSampsonRDaJordiSalas-SalvadóMDefMiguel A.MartÃnez-GonzálezMDaegMeir J.StampferMD, DrPHabcFrank B.HuMD, PhDabc
doi : 10.1016/j.jacc.2021.10.041
Volume 79, Issue 2, 18 January 2022, Pages 101-112
Olive oil consumption has been shown to lower cardiovascular disease risk, but its associations with total and cause-specific mortality are unclear.
Can Small Amounts of Olive Oil Keep the Death Away?∗
Susanna C.LarssonPhD
doi : 10.1016/j.jacc.2021.11.006
Volume 79, Issue 2, 18 January 2022, Pages 113-115
Magnetically Controlled Capsule Endoscopy for Assessment of Antiplatelet Therapy–Induced Gastrointestinal Injury
YalingHanMDa∗ZhuanLiaoMDb∗YiLiMDaXianxianZhaoMDbShurenMaMDaDanBaoMDaMiaohanQiuMDaJieDengMDcJinhaiWangMDcPengQuMDdChunmengJiangMDdShaobinJiaMDeShaoqiYangMDeLeishengRuMDfJiaFengMDfWeiGaoMDgYonghuiHuangMDgLingTaoMDh…Gregg W.StoneMDn
doi : 10.1016/j.jacc.2021.10.028
Volume 79, Issue 2, 18 January 2022, Pages 116-128
Gastrointestinal bleeding is the most frequent major complication of antiplatelet therapy. In patients at low bleeding risk, however, clinically overt gastrointestinal bleeding is relatively uncommon.
Gastrointestinal Injury Caused by Aspirin or Clopidogrel Monotherapy Versus Dual Antiplatelet Therapy∗
John A.BittlMDaLorenLaineMDbc
doi : 10.1016/j.jacc.2021.10.027
Volume 79, Issue 2, 18 January 2022, Pages 129-131
Risk-Adjusted, 30-Day Home Time After Transcatheter Aortic Valve Replacement as a Hospital-Level Performance Metric
AmgadMentiasMD, MSaNeilKeshvaniMDbMilind Y.DesaiMD, MBAaDharam J.KumbhaniMD, SMbMary VaughanSarrazinPhDcdYuboGaoPhDcdSamirKapadiaMDaEric D.PetersonMD, MPHbMichaelMackMDeSaketGirotraMD, SMcfAmbarishPandeyMD, MSCSb
doi : 10.1016/j.jacc.2021.10.038
Volume 79, Issue 2, 18 January 2022, Pages 132-144
Patient-centric measures of hospital performance for transcatheter aortic valve replacement (TAVR) are needed.
For TAVR, Home Is Where the Heart Is∗
Matthew W.SherwoodMD, MHSabAmit N.VoraMD, MPHcd
doi : 10.1016/j.jacc.2021.10.039
Volume 79, Issue 2, 18 January 2022, Pages 145-147
Feasibility and Potential Impact of Heart Transplantation From Adult Donors After Circulatory Death
ShivankMadanMD, MHAaOmarSaeedMDaStephen J.ForestMDbDaniel J.GoldsteinMDbUlrich P.JordeMDaSnehal R.PatelMDa
doi : 10.1016/j.jacc.2021.10.042
Volume 79, Issue 2, 18 January 2022, Pages 148-162
A shortage of donation after brain death (DBD) donors for heart transplantation (HT) persists. Recent improvements in organ procurement from donation after circulatory death (DCD) donors and promising early results of DCD-HTs from Europe and Australia have renewed interest in DCD-HT.
Heart Transplantation Using Organs From Donors Following Circulatory Death: The Journey Continues∗
Francis D.PaganiMD, PhD
doi : 10.1016/j.jacc.2021.11.008
Volume 79, Issue 2, 18 January 2022, Pages 163-165
Management of Atrial Fibrillation in Patients 75 Years and Older: JACC State-of-the-Art Review
Annabelle SantosVolgmanMDaGathaNairMDaRadmilaLyubarovaMDbFaisal M.MerchantMDcPamelaMasondAnne B.CurtisMDeNanette K.WengerMDcNeelum T.AggarwalMDfJames N.KirkpatrickMDgEmelia J.BenjaminMD, ScMh
doi : 10.1016/j.jacc.2021.10.037
Volume 79, Issue 2, 18 January 2022, Pages 166-179
The prevalence of atrial fibrillation (AF) is increasing as the population ages. AF treatment-related complications also increase markedly in older adults (defined as ≥75 years of age for this review). The older AF population has a high risk of stroke, bleeding, and death. Syncope and fall-related injuries are the most common reasons for nonprescription of oral anticoagulation (OAC), and are more common in older adults when OACs are used with antiarrhythmic drugs. Digoxin may be useful for rate control, but associations with increased mortality limit its use. Beyond rate and rhythm control considerations, stroke prophylaxis is critical to AF management, and the benefits of direct OACs, compared with warfarin, extend to older adults. Invasive procedures such as AF catheter ablation, pacemaker implantation/atrioventricular junction ablation, and left atrial appendage occlusion may be useful in appropriately selected cases. However, older adults have generally been under-represented in clinical trials.
Risk of Heart Failure in Patients With Nonalcoholic Fatty Liver Disease: JACC Review Topic of the Week
AlessandroMantovaniMDa∗Christopher D.ByrneMB, BChb∗GiovanniBenfariMDcStefanoBonapaceMDdTracey G.SimonMDefGiovanniTargherMDa
doi : 10.1016/j.jacc.2021.11.007
Volume 79, Issue 2, 18 January 2022, Pages 180-191
Heart failure (HF) and nonalcoholic fatty liver disease (NAFLD) are 2 conditions that have become important global public health problems. Emerging evidence supports a strong and independent association between NAFLD and the risk of new-onset HF, and there are multiple potential pathophysiological mechanisms by which NAFLD may increase risk of new-onset HF. The magnitude of this risk parallels the underlying severity of NAFLD, especially the level of liver fibrosis. Patients with NAFLD develop accelerated coronary atherosclerosis, myocardial alterations (mainly cardiac remodeling and hypertrophy), and certain arrhythmias (mainly atrial fibrillation), which may precede and promote the development of new-onset HF. This brief narrative review aims to provide an overview of the association between NAFLD and increased risk of new-onset HF, discuss the underlying mechanisms that link these 2 diseases, and summarize targeted pharmacological treatments for NAFLD that might also reduce the risk of HF.
The Heart Valve Collaboratory: A Disruptive Model in the Management of Valvular Heart Disease
Michael J.MackMDaMartin B.LeonMDbcChangfuWuPhDdBramZuckermanMDdHeart Valve Collaboratory Scientific Council
doi : 10.1016/j.jacc.2021.10.040
Volume 79, Issue 2, 18 January 2022, Pages 192-196
2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Writing Committee Members∗Jennifer S.LawtonMD, FAHA(Chair)†Jacqueline E.Tamis-HollandMD, FAHA, FACC, FSCAI(Vice Chair)‡SripalBangaloreMD, MHA, FACC, FAHA, FSCAI†Eric R.BatesMD, FACC, FAHA†Theresa M.BeckiePhD, FAHA†James M.BischoffMEd†John A.BittlMD, FACC, FAHA†Mauricio G.CohenMD, FACC, FSCAI§J. MichaelDiMaioMD†Creighton W.DonMD, PhD, FACC‖Stephen E.FremesMD, FACCMario F.GaudinoMD, PhD, MSCE, FACC, FAHA†Zachary D.GoldbergerMD, FACC, FAHA‡Michael C.GrantMD, MSE†Jang B.JaswalMS†Paul A.KurlanskyMD, FACC†RoxanaMehranMD, FACC†…Brittany A.ZwischenbergerMDâ€
doi : 10.1016/j.jacc.2021.09.005
Volume 79, Issue 2, 18 January 2022, Pages 197-215
The executive summary of the American College of Cardiology/American Heart Association/Society for Cardiovascular Angiography and Interventions coronary artery revascularization guideline provides the top 10 items readers should know about the guideline. In the full guideline, the recommendations replace the 2011 coronary artery bypass graft surgery guideline and the 2011 and 2015 percutaneous coronary intervention guidelines. This summary offers a patient-centric approach to guide clinicians in the treatment of patients with significant coronary artery disease undergoing coronary revascularization, as well as the supporting documentation to encourage their use.
2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines
Writing Committee Members∗Jennifer S.LawtonMD, FAHA(Chair)†Jacqueline E.Tamis-HollandMD, FAHA, FACC, FSCAI(Vice Chair)‡SripalBangaloreMD, MHA, FACC, FAHA, FSCAI†Eric R.BatesMD, FACC, FAHA†Theresa M.BeckiePhD, FAHA†James M.BischoffMEd†John A.BittlMD, FACC†Mauricio G.CohenMD, FACC, FSCAI§J. MichaelDiMaioMD†Creighton W.DonMD, PhD, FACC||Stephen E.FremesMD, FACCMario F.GaudinoMD, PhD, MSCE, FACC, FAHA†Zachary D.GoldbergerMD, FACC, FAHA‡Michael C.GrantMD, MSE†Jang B.JaswalMS†Paul A.KurlanskyMD, FACC†RoxanaMehranMD, FACC†…Brittany A.ZwischenbergerMDâ€
doi : 10.1016/j.jacc.2021.09.006
Volume 79, Issue 2, 18 January 2022, Pages e21-e129
The guideline for coronary artery revascularization replaces the 2011 coronary artery bypass graft surgery and the 2011 and 2015 percutaneous coronary intervention guidelines, providing a patient-centric approach to guide clinicians in the treatment of patients with significant coronary artery disease undergoing coronary revascularization as well as the supporting documentation to encourage their use.
Lessons From the COVID-19 Pandemic: Clinical Guidance and Respect for Science
DiptiItchhaporiaMD, FACC(President, American College of Cardiology)
doi : 10.1016/j.jacc.2021.12.001
Volume 79, Issue 2, 18 January 2022, Pages 216-219
Consistency of Benefit of Icosapent Ethyl by Background Statin Type in REDUCE-IT
NickpreetSinghMD, MSDeepak L.BhattMD, MPHMichaelMillerMDPh. GabrielStegMDEliot A.BrintonMDTerry A.JacobsonMDLixiaJiaoPhDJean-ClaudeTardifMDR. PrestonMasonPhDChristie M.BallantyneMDREDUCE-IT Investigators
doi : 10.1016/j.jacc.2021.11.005
Volume 79, Issue 2, 18 January 2022, Pages 220-222
Cardiovascular Disease Is the Condition, Air Pollution the Risk Factor, Fossil Fuel Combustion the Cause
Alan P.JacobsenMB BCh BAORoger S.BlumenthalMD
doi : 10.1016/j.jacc.2021.09.1386
Volume 79, Issue 2, 18 January 2022, Page e131
Reply: Cardiovascular Disease Is the Condition, Air Pollution the Risk Factor, Fossil Fuel Combustion the Cause
TiantianLiPhDYiZhangMPHMike Z.HePhDXiaomingShiMD
doi : 10.1016/j.jacc.2021.10.036
Volume 79, Issue 2, 18 January 2022, Page e133
